Author

Adanma Ayanambakkam

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Antibody-drug conjugate–associated pneumonitis (AAP) across novel first-in-human phase I trials: A pooled single-center analysis.

524 Background: Antibody-drug conjugates (ADCs) are increasingly used in cancer care; toxicities like Antibody-Drug Conjugate Associated Pneumonitis (AAP) have emerged as clinically significant & fatal adverse events. Data characterizing AAP across phase 1 trials is limited. Methods: We retrospectively collec...

Falah Fayaz, A. Aijaz, Hassan M. Abushukair et al. · JCO Oncology Practice · 0 citations

Open access Sep 2026

12 Farnesyl Transferase Inhibitor (FTI) Darlifarnib Combined with Cabozantinib in Renal Cell Carcinoma (RCC): Updated Phase 1a Results from FIT-001

Abstract Background VEGFR- and IO-targeted therapies for metastatic RCC have limitations that can lead to disease progression, highlighting the need for well-tolerated and effective combination strategies. VEGFR-TKI resistance occurs through multiple escape mechanisms, with the mTOR pathway playing a central role in su...

Adanma Ayanambakkam, Y. Zakharia, L. Rosen et al. · The Oncologist · 0 citations

Open access Sep 2026

22 Phase II Study of Cemiplimab ± Fianlimab Following SBRT for Oligometastatic Clear-Cell RCC (LAG-BOOST) (NCT07223541)

Abstract Background Oligometastatic clear-cell renal cell carcinoma (ccRCC) is a biologically distinct, often indolent state where metastasis-directed therapy, including metastasectomy or SBRT, provides durable local control and delays systemic therapy. Randomized prospective trial evidence demonstrates a survival bene...

Abhirami Das, S. Balkhi, A. Mitta et al. · The Oncologist · 0 citations